
Keywords: Eroom's law; innovation; drug approval; CVD; cardiovascular disease; FDA; Food and Drug Administration; NIH; National Institutes of Health; OD; orphan drug; PPMD; parent project muscular dystrophy; RCT; randomized controlled trials; R&D; research and de